IRVINE, Calif.--(BUSINESS WIRE)--TherOx, Inc., a privately held medical device company focused on improving treatment of acute myocardial infarction (AMI), announced that the U.S. Food and Drug ...

SAN DIEGO - A physician at Scripps Health's Prebys Cardiovascular Institute has become the first in the Western United States to treat heart attack patients with a new supersaturated oxygen (SSO2) ...

ROYAL OAK -- Over the past two decades, cardiologists have explored many different treatments to help prevent permanent heart damage after a heart attack. One treatment that appears to be very ...

Study Evaluates the Effectiveness of TherOx Supersaturated Oxygen (SSO 2) Therapy in Patients Presenting with Acute Anterior Myocardial Infarction with Successful Reperfusion Compared to Standard ...

Results of a clinical trial demonstrate that an infusion of blood that is "supersaturated" with oxygen (SS02) can reduce the amount of damaged heart muscle immediately following a life-threatening ...

ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced that the Centers for Medicare & Medicaid Services (CMS) ICD-10 Coordination ...

CHELMSFORD, Mass., October 31, 2022--(BUSINESS WIRE)--ZOLL, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that its TherOx SuperSaturated ...

A physician at Scripps Health's Prebys Cardiovascular Institute has become the first in the Western United States to treat heart attack patients with a new supersaturated oxygen (SSO2) system in an ...

CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL, an Asahi Kasei company, has been selected to exhibit SuperSaturated Oxygen (SSO 2) Therapy, which delivers high levels of dissolved oxygen directly to the ...

Zoll Medical Corp., of Chelmsford, Mass., received CE mark approval to market its second-generation Supersaturated Oxygen (SSO 2) Therapy in Europe and other countries that accept CE mark. The therapy ...